Clemson University baseball head coach Erik Bakich shares the mentality behind his team's decision to shake hands with ...

BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of ...

The following is a summary of “Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy,” published in the ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth driven by SYFOVRE, while navigating market challenges ...

THE last thing Lau remembered were the cries of his grade three pupils, shaking him and tapping his legs before he totally ...

Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and full year 2024 earnings conference call. (Operator Instructions) After the speaker's presentation, there will ...

Q4 2024 Earnings Call Transcript February 21, 2025 Operator: Good afternoon, and welcome to the Travere Therapeutics Fourth ...

Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II diabetic kidney disease cohort. Conducted ...

Sickle Cell Disease is a complex and debilitating genetic blood disorder that primarily affects people of African, ...

If approved, Fabhalta ®will be the only medicine indicated to selectively target the underlying cause of C3G 1, an ultra-rare, progressive kidney disease with no currently approved treatments 2-5 ...

Preeclampsia, a complication of pregnancy characterized by high blood pressure and high levels of protein in the urine ...

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in ...